Skip to main content

Table 1 Comparison of breast cancer risk factors and breast tumour characteristics according to those who were eligible for the study, those for whom we received pathology specimens and those who were included in the tissue microarrays, Nurses' Health Study (1976 to 1996)

From: Comparison of molecular phenotypes of ductal carcinoma in situand invasive breast cancer

  Eligible for TMA (n = 5610) Received pathology specimens (n = 3752) Included in TMA (n = 2897)
Means    
Age at diagnosis, y 56.4 57.4 57.5
Age at menarche, y 12.4 12.4 12.4
Age at first birth, y 25.4 25.4 25.3
Age at menopause, y 46.9 47.1 47.1
BMI at age 18, kg/m2 21.0 21.0 21.0
Parity 3.2 3.2 3.2
Alcohol g/week 6.6 6.1 6.2
Frequencies, n (%)    
Family history of BC 805 (14.4) 559 (14.9) 409 (14.1)
Nulliparous 430 (7.7) 281 (7.5) 211 (7.3)
Premenopausal 1345 (24.0) 782 (20.8) 600 (20.7)
Prior BBD 2662 (47.5) 1852(49.4) 1360 (47.0)
Current PMH user 1239 (33.8) 884 (34.2) 688 (34.6)
Year of diagnosis    
1976 to 1980 517 (9.4) 223 (6.1) 158 (5.6)
1980 to 1985 1066 (19.4) 565 (15.4) 431 (15.2)
1985 to 1990 1678 (30.6) 1152 (31.3) 899 (31.6)
1990 to 1996 2230 (40.6) 1739 (47.3) 1357 (47.7)
Tumour characteristics a    
DCIS 654 (11.7) 443 (11.8) 270 (9.3)
Invasive 4956 (88.3) 3309 (88.2) 2627 (90.7)
Tumour size    
Less than 2 cm 3162 (65.6) 2197 (66.7) 1685 (64.9)
More than 2 cm 1656 (34.4) 1098 (33.3) 911 (35.1)
Grade    
Well differentiated 319 (15.2) 240 (16.2) 176 (14.7)
Moderately 860 (41.0) 630 (42.4) 515 (43.1)
Poorly 919 (43.8) 615 (41.4) 505 (42.2)
Nodal involvement    
No nodes 3931 (70.1) 2684 (71.5) 2006 (69.2)
1 to 3 nodes 904 (16.1) 585 (15.6) 485 (16.7)
4 to 9 nodes 428 (7.6) 268 (7.1) 213 (7.4)
More than 10 nodes 228 (4.1) 140 (3.7) 129 (4.5)
Metastatic 119 (2.1) 75 (2.0) 64 (2.2)
Receptor status    
ER+ 2738 (74.5) 1953 (75.2) 1572 (75.3)
PR+ 2083 (61.2) 1518 (61.9) 1235 (62.3)
  1. aTumour characteristics abstracted from medical pathology reports. BC, breast cancer; BBD, benign breast disease; BMI, body mass index; DCIS, ductal carcinoma in situ; ER, oestrogen receptor; PMH, postmenopausal hormone; PR, progesterone receptor; TMA, tissue microarrays.